查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853776

新冠肺炎疫苗市场：依疫苗技术、剂量方案、给药途径、包装类型、通路、最终用户和采购模式划分－2025-2032年全球预测

COVID-19 Vaccines Market by Vaccine Technology, Dosage Regimen, Application Route, Packaging Type, Distribution Channel, End User, Procurement Model - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，新冠肺炎疫苗市场规模将达到 5,435.7 亿美元，复合年增长率为 10.92%。

关键市场统计数据
基准年 2024 2371.2亿美元
预计年份：2025年 2631亿美元
预测年份 2032 5435.7亿美元
复合年增长率 (%) 10.92%

为正在转型中的新冠肺炎疫苗生态系统提供权威指导，强调科学加速、监管调整和系统层面的韧性。

全球应对新冠疫情的行动永久再形成了疫苗研发模式、公共卫生运作以及整个医疗生态系统的商业性考量。过去几年，科学发现以前所未有的速度发展，催生了新型疫苗平台与传统方法并存的局面。同时，监管的紧迫性和严格的安全监督之间的相互作用，为适应性临床试验设计和滚动申请途径创造了新的先例。这些转变改变了製造商、付款者和医疗服务提供者评估风险、分配资源和确定投资优先顺序的方式。

在此背景下，供应链韧性已成为一项策略重点，涵盖互联互通的低温运输物流、原料采购和製造外包。公共卫生需求模式不断演变，疫苗接种率、加强针接受率以及多样化的需求都促使计画进行调整。市场参与企业和现有企业都必须在科学创新与复杂的配送需求以及日益严格的公众监督并存的环境中运作。因此，免疫产业的下一阶段将着重于可扩展的生产、透明的传播策略以及政策协调，以维持免疫计画的持续并维护公众信任。

科学基础的分化、供应链的演变以及公众行为如何从根本上重塑新冠疫苗接种的战略方法

新冠疫苗接种领域正经历多项变革性转变，这些转变持续影响各相关人员的策略决策。传讯RNA技术的科学成熟不仅展现了其快速应对新出现的变异株的能力，也影响未来疫苗研发平台的选择。同时，蛋白质次单元製剂的改进，包括优化的佐剂系统，为需要不同安全性和反应原性特征的人提供了更多选择。这些并行发展催生了更多元化的产品平臺，并为生产商和采购商拓宽了策略选择。

在营运层面，分销网络进行了调整，以平衡大规模疫苗宣传活动与透过临床和药房管道进行的有针对性的常规供应。政策框架也不断发展，以适应疫情时代的紧急准备，同时逐步将经验教训融入标准监管流程。供应链组织透过与委託製造和低温运输物流供应商建立策略伙伴关係得到改善，但在专业投入和产能瓶颈方面仍存在薄弱环节。此外，公众对加强针和儿童免疫接种的态度和行为动态持续影响着需求讯号，因此需要製定一项持续的参与策略，将透明的证据沟通与量身定制的接种方案相结合。

2025 年的关税环境将鼓励疫苗价值链的采购多元化、供应链风险降低以及对国内製造业的投资。

2025年关税及相关贸易措施的实施，使疫苗采购和分发的动态更加复杂，影响了成本结构、筹资策略和产业计画。关税变化影响了价值链上的各个环节，包括无菌生产所需的特殊原料、一次性生产组件和包装用品。这些调整促使采购团队重新评估其供应商组合，探索替代筹资策略，并专注于近岸外包和区域製造伙伴关係，以降低跨境成本波动带来的风险。

为因应关税风险加剧，供应链管理者加强了供应商资质认证流程，并寻求合约保障以确保生产连续性。低温运输物流供应商和契约製造製造商调整了定价模式，以反映跨境运输带来的成本增加和行政负担加重。同时，医疗系统和公共采购机构也重新评估了采购模式，更严格地审查了总到岸成本、前置作业时间和供应保障。关税情势也促使企业投资于国内灌装和包装产能，并建立优先考虑区域多元化的伙伴关係，从而提升战略韧性，但也需要资金配置和长期规划。

一种多维度细分观点，它将平台科学、管理策略、交付路线、包装、分销管道、终端用户人口统计和采购模式联繫起来

精细化的细分框架明确了产品开发、交付策略和商业性方法必须如何调整才能满足不同的需求。基于疫苗技术，区分灭活疫苗、mRNA疫苗和蛋白质次单元平台至关重要，因为每种途径的开发时间、生产规模和低温运输能力各不相同。基于接种方案，加强针、单剂和两剂等策略的差异会影响专案设计、依从性，并改变采购团队的供应週期。基于给药途径，肌肉注射或鼻腔给药的选择决定了给药基础设施的需求，并可能影响特定族群的接种率。

此外，基于包装类型（预填充式注射器与管瓶）的细分会对营运产生影响，包括浪费率、大型诊所的给药速度以及低温运输数量规划。诊所、医院和药局等分销管道的细分凸显了针对不同管道製定合作模式和报销方案的必要性。最终使用者分为青少年、成人和儿童群体，需要客製化临床证据包、安全沟通和给药策略才能实现目标。最后，政府采购和私人采购模式的细分会影响价格谈判、合约结构和存取途径，从而影响製造商如何建立商业报价和管理管道伙伴关係。综合这些细分，相关人员可以将产品属性与实际营运情况和人群需求相匹配。

不同的区域政策框架、生产能力和分销模式如何影响针对新冠疫苗取得和计画实施的有针对性方法

区域动态持续对疫苗政策、分发基础设施和商业性模式产生重大影响，并认识到这些差异对于制定有效策略至关重要。在美洲，大规模的公共采购项目与透过临床和药房管道产生的大量私人需求并存，从而形成了双轨分发模式，该模式强调灵活的供应合约和强大的低温运输物流。法规环境倾向于沿用现有的紧急核准机制，并逐步调整以规范上市后监测实践，而公共卫生宣传活动则日益重视加强推广和儿童接种策略。

欧洲、中东和非洲的监管环境更为多样化，有些市场拥有先进的监管体系，而有些市场则面临产能限制。这种多样性支持将区域製造地、有针对性的推广计划和资金筹措机制相结合的策略，以改善疫苗的可及性。官民合作关係和国际采购联盟在解决不公平现象和物流缺口方面发挥着至关重要的作用。在亚太地区，快速扩大生产规模的能力、不断发展的契约製造生态系统以及多样化的监管时间表，既为市场准入带来了机会，也带来了挑战。亚太地区的製药公司优先考虑供应可靠性、价格竞争力以及支持大规模疫苗宣传活动的能力，同时还要应对不断变化的区域监管预期和分销模式。政策制定者、製造商和服务提供者之间的合作对于在任何地区实施有效的疫苗计划至关重要。

疫苗研发商、委託製造和物流合作伙伴的策略行动凸显了协作、模组化产能扩张和通路多元化。

新冠疫苗领域的企业正采取多种策略性倡议，涵盖平台创新、配方改进、产能驱动型伙伴关係以及商业管道多元化等。领先的生物製药公司持续投资于下一代疫苗平台和佐剂系统，以扩大目标族群并提升安全性和耐受性。同时，受託製造厂商和低温运输物流专家正加强与疫苗研发者的合作，以提高填充和包装效率，并缓解先前阻碍疫苗快速部署的瓶颈。

策略合作已成为主导趋势，涵盖临床研究型大学、生物技术创新者和全球分销合作伙伴的联盟，在控製成本和风险的同时，加速了候选药物的研发进程。一些公司优先采用模组化生产设计，以实现产品类型之间的快速切换；而另一些公司则投资建设区域生产中心，以减少贸易中断的影响。商业策略日益将政府直接合约与药局和诊所管道结合，并辅以有针对性的教育宣传活动，以消除消费者的疑虑。总而言之，竞争格局有利于那些能够将科学研究敏捷性、营运扩充性以及值得信赖、透明的相关人员沟通相结合的机构。

疫苗相关人员可采取切实可行的策略性倡议，以提高生产弹性、低温运输透明度、监管参与度以及针对特定管道的准入方式。

产业领导者可以透过将策略投资与营运实际情况和公共卫生目标结合，加速产生影响。首先，优先发展能够适应多种平台和剂量配置的灵活生产能力，可以缩短新型製剂的研发时间，并支援对新出现的变体做出快速反应。其次，透过数位化追踪和整合物流，增强端对端低温运输的可视性，伙伴关係最大限度地减少浪费，并改善分配决策，尤其是在储存基础设施有限的环境中。第三，加强与监管机构的沟通，并专注于特定人群（例如青少年和儿童）的独特证据要求，可以简化核准途径，并提高专案的可信度。

同时，采取差异化的管道策略，充分考虑诊所、医院和药房的不同角色，既能确保更广泛的疫苗取得途径，又能满足地方政府的偏好。投资量身定制的风险沟通和社区参与项目，也有助于提高加强针的接种率，并保持疫苗偏好。最后，探索将长期供应承诺与私人采购选项结合的采购结构，既能支持公共卫生目标，也能保障商业性永续性。这些策略共同作用，可以增强疫苗接种的韧性，促进公平获取，并为疫苗利益相关人员创造更可预测的营运环境。

采用严谨的混合方法研究途径，整合相关人员访谈、监管和临床证据审查以及供应链案例研究三角验证。

本研究整合了一手和二手资料，建构了新冠疫苗领域的全貌。一手资料包括对生产製造、物流、监管事务和公共卫生管理等各领域相关人员的结构化访谈，从而获得关于营运挑战和策略应对的第一手观点。二手资料包括同侪审查文献、官方监管文件、临床试验註册资讯和产业技术报告，以佐证事实并交叉检验结论。透过供应链流程图和案例研究，对分销和采购实践数据进行三角验证，以突出实际应用中的经验教训。

本研究采用质性主题分析与情境比较评估结合的分析方法，旨在发现风险并识别因应策略。调查方法强调资讯来源的透明度和方法的可复製性，包括清晰记录访谈通讯协定、二手资料的纳入标准以及用于综合分析结果的框架。在适当情况下，研究还纳入了敏感度分析，以评估贸易政策变化、衍生方案的出现以及公众接受度如何影响营运重点。这种混合方法的研究成果既反映了实证证据，也体现了实践者的观点。

一份全面、具有前瞻性的审查报告强调了科学创新、营运韧性和支持性政策对于疫苗计画长期成功的重要性。

随着国际社会逐渐走出疫情初期紧急阶段，新冠疫苗生态系统正步入一个更为复杂和成熟的时期，科学创新、卓越营运和政策一致性将决定长期的成效。新型平台、不断演进的给药策略和多样化的交付模式相互作用，为提高人群保护水平提供了多种途径，同时也能解决公平性和可及性方面的问题。然而，要抓住这些机会，需要持续投资于可扩展的生产、更聪明的采购方式以及持续的公众参与，以维持公众信任和提高疫苗接种率。

展望未来，各组织能否成功很可能取决于其将科学进步与具有韧性的供应链和适应性强的监管策略相结合的能力。积极管理关税和贸易风险、投资模组化生产能力并采取因地制宜策略的相关人员，将更有能力提供可靠的疫苗供应。最终，该领域的进展将取决于公共和私营相关人员携手合作，共同解决问题，协调奖励，共用资源，并优先考虑能够最大限度造福公众健康的干预措施。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大针对新出现的SARS-CoV-2变种的二价和多效价疫苗配方，以提高免疫覆盖率
  • 鼻腔和黏膜疫苗候选药物在预防感染和提高患者依从性方面变得越来越重要。
  • 生物技术新兴企业与大型製药公司建立策略伙伴关係，以加速扩大疫苗生产能力
  • 下一代新冠疫苗在全球主要市场获得有条件核准，这是监管的里程碑。
  • 投资人对耐热mRNA疫苗平台的兴趣日益浓厚，这类平台可望促进疫苗在资源匮乏地区的分发。
  • 随着免疫特征和剂量指南的变化，儿科和孕产妇疫苗接种计划越来越受到重视。
  • 制定一项泛冠状病毒疫苗研究倡议，旨在广泛预防未来通用感染疾病的爆发

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依疫苗技术分類的COVID-19疫苗市场

  • 惰性
  • mRNA
  • 蛋白质次单元
    • 添加佐剂
    • 非佐剂

9. 新冠疫苗市场依剂量方案划分

  • 加强剂量
  • 单一剂量
  • 两剂疫苗

10. 新冠疫苗市场依给药途径划分

  • 肌肉内注射
  • 鼻内

第十一章：按包装类型分類的COVID-19疫苗市场

  • 预填充式注射器
  • 管瓶

12. 新冠疫苗市场按分销管道划分

  • 诊所
  • 医院
  • 药局

第十三章：按最终用户分類的 COVID-19 疫苗市场

  • 青春期
  • 成人
  • 孩子

14. 新冠疫苗市场采购模式

  • 政府采购
  • 私人购买

15. 各地区的 COVID-19 疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：按群体分類的新冠疫苗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：各国新冠疫苗市场概况

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • Moderna, Inc.
    • AstraZeneca PLC
    • Johnson & Johnson Services Inc.
    • China National Pharmaceutical Group Co., Ltd.
    • Sinovac Biotech Ltd.
    • Serum Institute of India Pvt. Ltd.
    • Novavax, Inc.
Product Code: MRR-02026C4C976F

The COVID-19 Vaccines Market is projected to grow by USD 543.57 billion at a CAGR of 10.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 237.12 billion
Estimated Year [2025] USD 263.10 billion
Forecast Year [2032] USD 543.57 billion
CAGR (%) 10.92%

An authoritative orientation to the transformed COVID-19 vaccine ecosystem highlighting scientific acceleration, regulatory adaptation, and system-level resilience

The global response to COVID-19 has permanently reshaped vaccine development paradigms, public health operations, and commercial considerations across the healthcare ecosystem. Over the past years, scientific discovery accelerated at an unprecedented pace, catalyzing novel vaccine platforms alongside traditional approaches. Simultaneously, the interplay between regulatory urgency and rigorous safety oversight created new precedents for adaptive clinical trial design and rolling submission pathways. These shifts have changed how manufacturers, payers, and providers evaluate risk, allocate resources, and prioritize investments.

Against this backdrop, supply chain resilience emerged as a strategic priority, intersecting cold chain logistics, raw material sourcing, and contract manufacturing capacity. Public health demand patterns evolved as populations experienced heterogeneous rates of vaccine uptake, booster acceptance, and variant-driven needs, prompting programmatic adjustments. Market entrants and incumbents alike must now operate within a landscape where scientific innovation coexists with complex distribution requirements and heightened public scrutiny. Consequently, the industry's next phase emphasizes scalable manufacturing, transparent communication strategies, and policy alignment to sustain immunization programs and maintain public trust.

How scientific platform diversification, supply chain evolution, and public behavior are fundamentally reshaping strategic approaches to COVID-19 vaccination delivery

The landscape of COVID-19 vaccination is defined by several transformative shifts that continue to influence strategic decision-making across stakeholders. Scientific maturation of messenger RNA technology has not only demonstrated rapid response capability against emerging variants but has also influenced platform selection for future vaccine development. Concurrently, improvements in protein subunit formulations, including optimized adjuvant systems, have expanded options for populations that require different safety and reactogenicity profiles. These parallel developments have created a more diversified product pipeline and widened strategic choices for manufacturers and purchasers.

Operationally, distribution networks have adapted to balance high-throughput mass vaccination campaigns with targeted, routine delivery through clinical and pharmacy channels. Policy frameworks evolved to accommodate pandemic-era emergency measures while progressively integrating lessons into standard regulatory processes. Supply chain orchestration improved through strategic partnerships with contract manufacturers and cold chain logistics providers, yet vulnerabilities remain in specialized inputs and capacity bottlenecks. Moreover, public sentiment and behavioral dynamics around booster acceptance and pediatric immunization continue to shape demand signals, necessitating ongoing engagement strategies that combine transparent evidence communication with tailored access programs.

The 2025 tariff environment catalyzing sourcing diversification, supply chain de-risking, and domestic manufacturing investment across the vaccine value chain

The imposition of tariffs and related trade measures in 2025 has added a complex layer to vaccine procurement and distribution dynamics, influencing cost profiles, sourcing strategies, and operational planning. Tariff changes affected inputs across the value chain, including specialized raw materials, single-use manufacturing components, and packaging supplies that are critical to sterile production. These adjustments prompted procurement teams to reassess supplier portfolios, seek alternative sourcing strategies, and increase emphasis on nearshoring or regional manufacturing partnerships to reduce exposure to cross-border cost volatility.

In response to heightened tariff risk, supply chain managers intensified supplier qualification processes and pursued contractual protections to insulate production continuity. Cold chain logistics providers and contract manufacturers recalibrated pricing models to reflect the incremental costs and administrative burdens associated with cross-border movements. At the same time, health systems and public purchasers evaluated procurement models with more pronounced scrutiny on total landed cost, lead times, and supply guarantees. The tariff landscape also incentivized investment in domestic fill-and-finish capacity and partnerships that prioritized geographic diversification, thereby improving strategic resilience but requiring capital allocation and longer-term planning.

A multi-dimensional segmentation perspective connecting platform science, dosage strategy, delivery route, packaging, distribution channels, end-user cohorts, and procurement models

A granular segmentation framework clarifies where product development, delivery strategies, and commercial approaches must be tailored to meet heterogeneous needs. Based on Vaccine Technology, distinctions among Inactivated, mRNA, and Protein Subunit platforms matter because each pathway demands different development timelines, manufacturing footprints, and cold chain capabilities; notably, Protein Subunit vaccines are further delineated between Adjuvanted and Non Adjuvanted formulations, which influence immunogenicity profiles and target population suitability. Based on Dosage Regimen, differences across Booster Dose, Single Dose, and Two Dose strategies drive programmatic design, influence adherence considerations, and alter supply forecasting horizons for procurement teams. Based on Application Route, the choice between Intramuscular and Intranasal delivery defines administration infrastructure needs and can affect acceptance rates among specific populations.

Further segmentation based on Packaging Type-Prefilled Syringe versus Vial-has operational implications for wastage rates, administration speed in mass clinics, and cold chain volume planning. Distribution Channel segmentation spanning Clinic, Hospital, and Pharmacy underscores the necessity of channel-specific engagement models and reimbursement considerations. End User segmentation across Adolescent, Adult, and Child cohorts requires tailored clinical evidence packages, safety communications, and dosing strategies to achieve uptake targets. Finally, Procurement Model segmentation between Government Procurement and Private Purchase shapes pricing negotiations, contracting structures, and access pathways, thereby influencing how manufacturers structure commercial offers and manage channel partnerships. Together, these segmentation lenses enable stakeholders to match product attributes to operational realities and population needs.

How differentiated regional policy frameworks, manufacturing capacity, and distribution models are shaping targeted approaches to COVID-19 vaccine access and program execution

Regional dynamics continue to exert significant influence on vaccine policy, distribution infrastructure, and commercial approaches, and recognizing these differences is essential to effective strategy formation. In the Americas, large public procurement programs coexist with substantial private demand through clinical and pharmacy channels, leading to a dual-track distribution model that emphasizes flexible supply agreements and robust cold chain logistics. The regulatory environment favors established emergency authorization mechanisms and progressive alignment toward standardized post-market surveillance practices, while public health campaigns increasingly focus on booster outreach and pediatric dosing strategies.

In Europe, Middle East & Africa, the landscape is more heterogeneous, with advanced regulatory systems in some markets and capacity constraints in others. This diversity drives strategies that combine regional manufacturing hubs, targeted deployment programs, and tailored financing mechanisms to improve access. Public-private partnerships and international procurement consortia play a pivotal role in addressing inequities and logistical gaps. In Asia-Pacific, rapid manufacturing scale-up capabilities, a growing contract manufacturing ecosystem, and diverse regulatory timelines create both opportunities and complexity for market entrants. Regional players emphasize supply reliability, competitive pricing, and the ability to support large-scale immunization campaigns, while also navigating evolving local regulatory expectations and distribution modalities. Across all regions, collaboration between policymakers, manufacturers, and service providers remains a critical enabler of effective vaccine program implementation.

Strategic behaviors among vaccine developers, contract manufacturers, and logistics partners revealing collaboration, modular capacity expansion, and channel diversification

Companies operating in the COVID-19 vaccine space demonstrate a range of strategic postures, from platform innovation and incremental formulation improvements to capacity-focused partnerships and diversified commercial channels. Leading biopharmaceutical firms have continued to invest in next-generation vaccine platforms and adjuvant systems to widen their addressable populations and improve safety and tolerability profiles. At the same time, contract manufacturing organizations and cold chain logistics specialists have strengthened alliances with vaccine developers to expand fill-and-finish throughput and reduce bottlenecks that previously constrained rapid deployment.

Strategic collaboration has become a dominant theme, with alliances spanning clinical research universities, biotech innovators, and global distribution partners to accelerate candidate progression while managing cost and risk. Some companies have prioritized modular manufacturing designs that facilitate rapid switching between vaccine types, whereas others have invested in regional production footprints to mitigate trade-related disruptions. Commercial strategies increasingly blend direct government contracting with pharmacy and clinic channel engagement, supported by targeted educational campaigns to address hesitancy. Overall, the competitive dynamic rewards organizations that can combine scientific agility with operational scalability and credible, transparent stakeholder communication.

Practical strategic moves for vaccine stakeholders to enhance manufacturing flexibility, cold chain visibility, regulatory engagement, and channel-specific access approaches

Industry leaders can accelerate impact by aligning strategic investments with operational realities and public health objectives. First, prioritizing flexible manufacturing capacity-capable of handling multiple platforms and dose configurations-reduces time-to-deployment for novel formulations and supports rapid response to emergent variants. Second, strengthening end-to-end cold chain visibility through digital tracking and integrated logistics partnerships minimizes wastage and improves allocation decisions, particularly in contexts with constrained storage infrastructure. Third, cultivating regulatory engagement that focuses on clear evidence requirements for specific populations, such as adolescents and children, streamlines approval pathways and bolsters program confidence.

In parallel, adopting differentiated channel strategies that recognize the distinct roles of clinics, hospitals, and pharmacies ensures broader access while addressing local administration preferences. Investment in tailored risk communication and community engagement programs can improve booster acceptance and sustain immunization momentum. Finally, exploring procurement structures that combine long-term supply commitments with options for private purchase supports both public health objectives and commercial sustainability. Together, these actions enhance resilience, support equitable access, and create a more predictable operating environment for vaccine stakeholders.

A rigorous mixed-methods research approach integrating stakeholder interviews, regulatory and clinical evidence review, and supply chain case study triangulation

This research synthesizes primary and secondary evidence to construct a comprehensive view of the COVID-19 vaccine landscape. Primary inputs included structured interviews with stakeholders across manufacturing, logistics, regulatory affairs, and public health administration, providing firsthand perspectives on operational challenges and strategic responses. Secondary inputs encompassed peer-reviewed literature, public regulatory filings, clinical trial registries, and industry technical reports to ensure factual grounding and cross-validation of claims. Data on distribution and procurement practices were triangulated through supply chain process mapping and case studies that highlight real-world implementation lessons.

Analytical methods combined qualitative thematic analysis with comparative scenario assessment to surface risks and identify resilience strategies. The methodology emphasized transparency in sourcing and reproducibility in approach, with clear documentation of interview protocols, inclusion criteria for secondary sources, and the analytical frameworks used to synthesize findings. Where appropriate, the research incorporated sensitivity checks to evaluate how changes in trade policy, variant emergence, or public acceptance could alter operational priorities. This mixed-method approach ensures that insights reflect both empirical evidence and pragmatic perspectives from practitioners.

A forward-looking synthesis that underscores the necessity of aligning scientific innovation, resilient operations, and collaborative policy to secure long-term vaccine program success

As the global community moves beyond the initial pandemic emergency phase, the COVID-19 vaccine ecosystem is settling into a more complex, mature era where scientific innovation, operational excellence, and policy coherence determine long-term outcomes. The interplay of novel platforms, evolving dosage strategies, and diversified delivery models offers multiple pathways to improve population protection while addressing equity and access concerns. However, realizing these opportunities requires continued investment in scalable manufacturing, smarter procurement practices, and sustained public engagement to maintain confidence and uptake.

Looking ahead, the capacity to integrate scientific advances with resilient supply chains and adaptive regulatory strategies will define organizational success. Stakeholders that proactively manage tariff and trade risks, invest in modular production capabilities, and tailor approaches to regional realities will be better positioned to deliver reliable access to vaccines. Ultimately, the sector's progress will depend on collaborative problem-solving across public and private actors to align incentives, share capacity, and prioritize interventions that maximize public health benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of bivalent and multivalent vaccine formulations targeting emerging SARS-CoV-2 variants to enhance immune coverage
  • 5.2. Rising emphasis on intranasal and mucosal vaccine candidates to improve transmission blockage and patient compliance
  • 5.3. Strategic partnerships between biotech startups and big pharma for accelerated vaccine manufacturing capacity scaling
  • 5.4. Regulatory milestone of conditional approvals for next-generation COVID vaccines in key global markets
  • 5.5. Growing investor interest in thermostable mRNA vaccine platforms to facilitate distribution in low-resource settings
  • 5.6. Increased focus on pediatric and maternal vaccination programs amid changing immunity profiles and dosing guidelines
  • 5.7. Development of pan-coronavirus vaccine research initiatives aimed at broad protection against future zoonotic outbreaks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Vaccines Market, by Vaccine Technology

  • 8.1. Inactivated
  • 8.2. mRNA
  • 8.3. Protein Subunit
    • 8.3.1. Adjuvanted
    • 8.3.2. Non Adjuvanted

9. COVID-19 Vaccines Market, by Dosage Regimen

  • 9.1. Booster Dose
  • 9.2. Single Dose
  • 9.3. Two Dose

10. COVID-19 Vaccines Market, by Application Route

  • 10.1. Intramuscular
  • 10.2. Intranasal

11. COVID-19 Vaccines Market, by Packaging Type

  • 11.1. Prefilled Syringe
  • 11.2. Vial

12. COVID-19 Vaccines Market, by Distribution Channel

  • 12.1. Clinic
  • 12.2. Hospital
  • 12.3. Pharmacy

13. COVID-19 Vaccines Market, by End User

  • 13.1. Adolescent
  • 13.2. Adult
  • 13.3. Child

14. COVID-19 Vaccines Market, by Procurement Model

  • 14.1. Government Procurement
  • 14.2. Private Purchase

15. COVID-19 Vaccines Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. COVID-19 Vaccines Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. COVID-19 Vaccines Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Pfizer Inc.
    • 18.3.2. Moderna, Inc.
    • 18.3.3. AstraZeneca PLC
    • 18.3.4. Johnson & Johnson Services Inc.
    • 18.3.5. China National Pharmaceutical Group Co., Ltd.
    • 18.3.6. Sinovac Biotech Ltd.
    • 18.3.7. Serum Institute of India Pvt. Ltd.
    • 18.3.8. Novavax, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COVID-19 VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 307. GCC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. GCC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. GCC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 312. GCC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 313. GCC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 314. GCC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 315. GCC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. GCC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. GCC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. GCC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. GCC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. GCC COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. GCC COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 324. GCC COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL,